Twenty-two team members of Quantum Pharmaceutical took part in this year’s ‘Big Zip’ charity zip-wire jump last Saturday at Newcastle’s Tyne Bridge.
04 November 2010
Hard on the heels of good news for life sciences from the Spending Review and £50 million from the Technology Strategy Board for stratified medicine, two new initiatives have been launched by Universities and Science Minister David Willetts.
26 October 2010
With access, cost and quality concerns plaguing pharmaceutical delivery systems both in the US as well as globally, the Next Generation Pharmaceutical Drug Discovery committee has been formed to confront, assess and deliver new strategies to secure the future of the industry. Meeting in Miami, Florida, the committee will discuss the state-of-play for personalized medicine, R&D challenges, translational medicine, imaging techniques and novel biomarkers – all connected by the pulse of the sector: the call for open innovation.
08 October 2010
Today, David Rutley, MP for Macclesfield, will officially open Cyprotex’s new toxicology facility – branded as Cyprotox® – at its headquarters in Macclesfield, UK.
01 October 2010
Ghent University, the University of Antwerp and BioTools Europe Ltd have partnered to create the European Centre for Chirality (EC2), which is dedicated to advancing understanding of the part chirality plays in biological processes.
24 September 2010
Ten amateur cyclists from pharmaceutical manufacturer Quantum Pharmaceutical have completed a gruelling thousand mile charity bike ride to raise £5000 for Marie Curie Cancer Care.
16 September 2010
Cancer Research UK and Cancer Research Technology have reached an agreement with AstraZeneca to take compound AZD-3965, a first-of-its-kind experimental drug that could treat a range of cancers, into clinical trial.
13 September 2010
Charles River Laboratories, a global preclinical contract research organization, now offers BlueScreen HC Screening services for the early detection of genotoxicity.
09 September 2010
MorphoSys AG has announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics.
03 September 2010
Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany, to evaluate new leptin antagonist peptides as potential experimental treatments, initially in the area of gynaecological diseases, including cancer.
25 August 2010
Cancer Research Technology has signed a deal to provide biotech company ValiRx PLC with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
16 August 2010
Numerate and Intellikine have announced the successful conclusion of their research collaboration to discover novel small-molecule compounds targeting the PI3K/mTOR signaling pathway.
11 August 2010
Secretary of State for Business, Innovation and Skills Vince Cable today announced the appointment of Sir John Savill as Chief Executive and Deputy Chair of the Medical Research Council.
30 July 2010
Thermo Fisher Scientific has announced a landmark collaboration that aims to introduce mass-spectrometry-based workflows and technologies into Japan to advance personalized medicine and healthcare.
27 July 2010
Royal Philips Electronics and Dako, a Danish company specializing in tissue-based cancer diagnostics, have signed an agreement to integrate a selection of Dako's image analysis applications into Philips' future digital pathology solutions.
22 July 2010
Cancer Research Technology and Medical Research Council Technology plan to ‘swap’ medical discoveries to accelerate the translation of early scientific research into patient benefit.
15 July 2010
Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a complete kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome.
13 July 2010
Some of pharmaceutical’s big boys, for example Pfizer, have faced well-documented challenges over the last 12 months. The industry is only too aware of this and understands that now is the time to look at new processes and a change in the way they have traditionally done business.
07 July 2010
Marinomed Biotechnologie has signed a licensing agreement with Boehringer Ingelheim to market Marinomed’s anti-viral nasal spray for treating the common cold in Europe (except Austria and UK), Russia and CIS, South America, parts of Asia, and Australia.
29 June 2010
Teva is investing £37 million to expand its Stouffville production plant and Ontario is providing a £4.25 million grant to Teva Canada, which will retain 182 workers and hire 20 more.
02 June 2010